Latest news

• Shire's Q3 net profit doubles

  Products that performed particularly well in the quarter included ADHD treatments Vyvanse (lisdexamfetamine) and Adderall XR (amphetamine, dextroamphetamine mixed salts).

• Shire ADHD scholarship programme

  use as adjunctive therapy to stimulants; the extended-release drug Vyvanse (lisdexamfetamine dimesylate), which was approved in the US in 2007; and Adderall XR (dextroamphetamine and amphetamine), which was approved in

• New use cleared for Shire ADHD drug

  The company's ADHD portfolio also includes the extended-release drug VyVanse (lisdexamfetamine dimesylate), which was approved in the US in 2007, and Adderall XR (dextroamphetamine and amphetamine), which was approved

• Malcolm's Market Eye: 28 July to 3 August 2007

  Shire wants the drug to take over from Adderall XR (amphetamine/dextroamphetamine), its blockbuster drug now threatened by generic competition, because in 2009 it loses patent protection.

• Malcolm's Market Eye, 27 February 2007

  Shire has gained full control over Vyvanse, as it needs a successor to Adderall XR (amphetamine/ dextroamphetamine extended-release), its biggest-selling ADHD drug, which soon loses patent protection.